News Sentiment

RGEN sentiment intelligence

Repligen Corporation news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 56 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Instruments & Supplies Read-through group
Latest close 144.24 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

79/100 classification confidence.

Company focus 56

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+1.3% over one week, +10.5% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Issuer RGEN (NASDAQ: RGEN) plans 530-share sale by Form 144 filer

Market Reaction

Balanced read

62/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 79/100 classification
One-week reaction 1.3% Price digesting
Trend fit Trend inactive 10.5% over four weeks
Fair value -2.3% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 17
Neutral 35
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 56
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
TradingView 12
Market source 12
Stock Titan 7
simplywall.st 4
GuruFocus 3
AD HOC NEWS 2
Moomoo 2
Quiver Quantitative 2

Event Lens

What the news is about

Classified themes
Market update 30
Earnings 18
Analyst action 3
Guidance 2
Balance sheet 1
Macro sensitivity 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 56
TradingView Direct company coverage

RGEN5964422 Bond Profile — Key Metrics

This article provides key metrics for the RGEN5964422 bond issued by Repligen Corporation. The bond has a 1.0% coupon rate and matures on December 15, 2028, with an outstanding amount of $600 million. Repligen Corp. is a global life sciences company founded in 1981, specializing

Tone
Neutral 50/100
Event
Market update
Published
16 Jul 2026 08:12
Source
TradingView
scanx.trade Direct company coverage

Repligen to report Q2 2026 financial results on July 28

Repligen Corporation is set to announce its second-quarter 2026 financial results on July 28, 2026, covering the period ended June 30, 2026. The company will issue a press release before market open, followed by a conference call at 8:00 a.m. ET to discuss the results and provide

Tone
Positive 73/100
Event
Earnings
Published
15 Jul 2026 14:11
Source
scanx.trade
Stock Titan Direct company coverage

Repligen Schedules 8 a.m. ET Webcast for July 28 Results

Repligen (NASDAQ: RGEN) announced it will report its Q2 2026 financial results on Tuesday, July 28, 2026. A press release will be issued before market open, followed by a conference call and webcast at 8:00 a.m. ET to discuss business updates and results for the quarter ended Jun

Tone
Neutral 50/100
Event
Earnings
Published
15 Jul 2026 12:11
Source
Stock Titan
GlobeNewswire Direct company coverage

Repligen to Report Second Quarter 2026 Financial Results

Repligen Corporation (NASDAQ:RGEN) announced it will report its second quarter 2026 financial results on Tuesday, July 28, 2026. The company will issue a press release before market open and host a conference call at 8:00 a.m. ET to discuss business updates and financial results

Tone
Neutral 50/100
Event
Earnings
Published
15 Jul 2026 11:11
Source
GlobeNewswire
TradingView Direct company coverage

ETFs Investing in Repligen Corporation Stocks

This article lists numerous Exchange Traded Funds (ETFs) that hold Repligen Corporation stocks, categorizing them by issuer, management style, focus, expense ratio, and assets under management (AUM). It provides key financial metrics for each ETF, including market value of Replig

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 19:42
Source
TradingView
Ad-hoc-news.de Direct company coverage

Repligen stock trades steadily as bioprocessing demand shapes investor focus

Repligen stock (RGEN) is influenced by its role in the high-growth bioprocessing sector, where demand for biologics and advanced therapies drives recurring revenue. Investors focus on long-term factors like margins, capacity expansion, and broad biologics demand, rather than shor

Tone
Positive 71/100
Event
Earnings
Published
09 Jul 2026 17:35
Source
Ad-hoc-news.de
Stock Traders Daily Direct company coverage

(RGEN) and the Role of Price-Sensitive Allocations

This article provides an in-depth stock analysis for Repligen Corporation (NASDAQ: RGEN), highlighting neutral near-term readings and strong mid-term sentiment that may be stalling. It details AI-generated trading strategies including position trading, momentum breakout, and risk

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 16:10
Source
Stock Traders Daily
Simply Wall Street Direct company coverage

Should Repligen's (RGEN) Russell Growth Index Removal Require Action From Current Investors?

Repligen (RGEN) was removed from multiple Russell growth benchmarks, including the Russell 1000 Growth and 3000 Growth Indexes, which may affect its liquidity and shareholder base. While this shift doesn't alter immediate operational drivers like order trends or margins, it highl

Tone
Neutral 50/100
Event
Balance sheet
Published
08 Jul 2026 05:10
Source
Simply Wall Street
AD HOC NEWS Direct company coverage

Repligen Corp business overview and stock context

Repligen Corp specializes in bioprocessing technologies for biologic drug production, supplying equipment and solutions to pharmaceutical and biotech companies. Its business model focuses on filtration, separation, and fluid management systems, benefiting from the growing demand

Tone
Positive 66/100
Event
Macro sensitivity
Published
07 Jul 2026 22:46
Source
AD HOC NEWS
Moomoo Direct company coverage

REPLIGEN CORP : BENCHMARK RAISES TO BUY FROM HOLD

Benchmark has upgraded its rating for Repligen Corporation from Hold to Buy. This indicates an increased positive outlook on the company's stock performance.

Tone
Positive 72/100
Event
Guidance
Published
07 Jul 2026 20:11
Source
Moomoo
Stock Titan Direct company coverage

If You Invested $1,000 in Repligen (RGEN)

This article analyzes the historical performance of investing $1,000 in Repligen (RGEN) over 1, 5, and 10 years, detailing the total return and Compound Annual Growth Rate (CAGR). It also provides an annual performance comparison of RGEN against the S&P 500 and offers a company o

Tone
Positive 64/100
Event
Market update
Published
04 Jul 2026 08:41
Source
Stock Titan
www.marketscreener.com Direct company coverage

Repligen Corporation(NasdaqGS: RGEN) dropped from Russell Midcap Growth Benchmark

Repligen Corporation (NasdaqGS: RGEN) has been removed from the Russell Midcap Growth Benchmark. This news follows a series of recent events for the company, including presentations at healthcare conferences and its Q1 2026 earnings report, where it posted better-than-expected ad

Tone
Negative 28/100
Event
Earnings
Published
29 Jun 2026 16:56
Source
www.marketscreener.com
TradingView Direct company coverage

Price to sales forward of Repligen Corporation – NASDAQ:RGEN

The article provides a financial metric for Repligen Corporation (NASDAQ: RGEN), specifically its forward price-to-sales ratio. It indicates that the market was closed at the time of publication and there were no trades. The content offers a snapshot of a financial data point for

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 04:10
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Repligen Corporation – NASDAQ:RGEN

This page provides financial information for Repligen Corporation (NASDAQ:RGEN), specifically focusing on its forward Price to Earnings (P/E) ratio. It indicates that the market for RGEN is currently closed with no trades. The content is primarily a data placeholder from TradingV

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 21:41
Source
TradingView
TradingView Direct company coverage

Price to book forward of Repligen Corporation – BX:RGN

The article displays the "Price to book forward" for Repligen Corporation (RGN) on the BX Swiss exchange. It notes that the market is currently closed with no trades. The content primarily shows financial data available through TradingView, including a historical overview, and hi

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 13:41
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Repligen Corporation – NASDAQ:RGEN

This article displays the enterprise value to EBITDA forward for Repligen Corporation, traded as RGEN on the Nasdaq Stock Market. It presents the period, value, and change information for this financial metric. The content is primarily a data point from TradingView's financial an

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 12:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Repligen Corporation – BX:RGN

The article focuses on the "Enterprise value to revenue forward" metric for Repligen Corporation, traded on the BX Swiss exchange under the symbol RGN. It presents this financial data point for the company. The content primarily highlights where to find this financial detail with

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 10:10
Source
TradingView
TradingView Direct company coverage

Repligen Corporation Actuals & Estimates (DUS:RGN)

This article provides financial actuals and estimates for Repligen Corporation (DUS:RGN), including income statement, balance sheet, and cash flow data, alongside analyst price targets. It covers frequently asked questions regarding its stock ticker, forecast, historical prices,

Tone
Neutral 50/100
Event
Guidance
Published
27 Jun 2026 03:41
Source
TradingView
GuruFocus Direct company coverage

Insider Sell: Jason Garland Sells Shares of Repligen Corp (RGEN)

Jason Garland, CFO of a Repligen Corp (RGEN) subsidiary, sold 733 shares of the company on June 25, 2026. This transaction leaves him with 19,359 shares. The stock, trading at $145 with a market cap of $8.292 billion, is considered modestly undervalued with a price-to-GF-Value ra

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 02:09
Source
GuruFocus
TradingView Direct company coverage

Repligen Corporation Actuals & Estimates (NASDAQ:RGEN)

This article provides an overview of Repligen Corporation (NASDAQ: RGEN) stock, including its current price, market capitalization, and historical performance. It details financial actuals and estimates, analyst forecasts for future price targets, and information on earnings repo

Tone
Positive 64/100
Event
Earnings
Published
26 Jun 2026 21:09
Source
TradingView
Stock Titan Direct company coverage

Repligen (RGEN) CFO completes 733-share Rule 10b5-1 stock sale

Repligen's CFO, Jason K. Garland, sold 733 shares of the company's common stock at $145 per share in a pre-planned transaction. This sale, totaling $106,285, was executed under a Rule 10b5-1 trading plan adopted on December 8, 2025. Following the transaction, Garland directly own

Tone
Negative 40/100
Event
Market update
Published
26 Jun 2026 20:09
Source
Stock Titan